Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 8/22/17 → 3/21/22 |
Funding
- Rebiotix Inc: $22,046.00
17-ID-207: A Phase 3 Prospective, Randomized, Double-Blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection
- Greenberg, Richard (PI)